1. Home
  2. GRC vs ATAI Comparison

GRC vs ATAI Comparison

Compare GRC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

HOLD

Current Price

$74.89

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$4.54

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRC
ATAI
Founded
1933
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
GRC
ATAI
Price
$74.89
$4.54
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$15.88
AVG Volume (30 Days)
86.5K
4.1M
Earning Date
04-23-2026
05-11-2026
Dividend Yield
1.04%
N/A
EPS Growth
32.03
N/A
EPS
0.68
N/A
Revenue
$682,389,000.00
$4,089,000.00
Revenue This Year
$6.62
N/A
Revenue Next Year
$4.66
N/A
P/E Ratio
$110.06
N/A
Revenue Growth
3.44
1227.60
52 Week Low
$34.96
$2.00
52 Week High
$79.54
$6.73

Technical Indicators

Market Signals
Indicator
GRC
ATAI
Relative Strength Index (RSI) 55.18 61.78
Support Level $43.10 $3.46
Resistance Level $79.02 $4.68
Average True Range (ATR) 2.25 0.22
MACD -0.28 0.03
Stochastic Oscillator 62.97 93.94

Price Performance

Historical Comparison
GRC
ATAI

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: